Virax Biolabs Group Ltd. VRAX
What this company does
Written from the business description in Virax Biolabs Group Ltd's annual report to the U.S. Securities and Exchange Commission, filed 6 July 2026. Every sentence was checked against that document before publication.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 110 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | · | · | · |
| Income tax $B | −0.0 | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | · | · |
| EPS, diluted $ | −1.62 | −3.36 | −5.13 | −1.79 | · |
| Dividend / sh $ | · | · | · | · | · |
| Payout % | · | · | · | · | · |
| ROE % | −109.6 | −92.9 | −133.9 | · | · |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 5 of 19 fiscal years. 72 checks could not be computed.